Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer and QIAGEN subsidiary enter into partnership

Pfizer and QIAGEN subsidiary enter into partnership

5th February 2010

Pfizer has forged a new partnership with QIAGEN’s fully owned subsidiary DxS, which will see the two work together to develop a companion diagnostic test kit for PF-04948568 (CDX-110).

The compound is an immunotherapy vaccine currently in the development stages for the treatment of glioblastoma multiforme (GBM).

PF-04948568 (CDX-110) is a peptide vaccine which targets an epidermal growth factor receptor that is only present in cancer cells.

QIAGEN’s assay is designed to identify those patients whose tumours express this mutation, therefore allowing for more focused treatment.

Pfizer received the worldwide licence to PF-04948568 (CDX-110) from Celldex Therapeutics in April 2008.

Dr Stephen Little, vice-president of personalised healthcare for QIAGEN, commented: “We are very pleased to have signed this agreement with Pfizer, as it is another important step toward the realisation of personalised medicine.”

Earlier this week, QIAGEN unveiled its latest product – the QIAsymphony AS.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.